Literature DB >> 1520538

Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction.

S Aoki-Sei1, R Yarchoan, S Kageyama, D T Hoekzema, J M Pluda, K M Wyvill, S Broder, H Mitsuya.   

Abstract

We established a method to estimate the amounts of HIV-1 particles in plasma from patients with HIV-1 infection by using polymerase chain reaction (PCR) following reverse transcription (RT) of viral RNA (RNA-PCR) and assessed the potential usefulness of this approach to monitor the changes of viral load in patients with AIDS or AIDS-related complex (ARC) receiving 2',3'-dideoxyinosine (ddI). Plasma samples were obtained from 77 patients with HIV-1 infection (49 AIDS/ARC and 28 asymptomatic seropositives). Following ultracentrifugation of plasma, RNA was extracted from the pelleted virus and subjected to RT and PCR. The number of HIV-1 virus particles in each sample was determined using known amounts of HIV-1 DNA as reference control for PCR. The current plasma RNA-PCR technique quantitatively detected HIV-1 particles in plasma from 76 of 77 (98.7%) HIV-1-infected individuals examined. The numbers of HIV-1 particles in plasma from patients with AIDS or ARC were markedly higher than those in plasma from asymptomatic seropositive individuals (p less than 0.0001). Higher levels of plasma HIV-1 particle numbers were detected in individuals with lower CD4+ T cell counts. Patients (n = 10) who received oral ddI at doses greater than or equal to 6.4 mg/kg/day for 8 to 14 weeks had a profound decrease in plasma HIV-1 particle numbers (p = 0.0051). Patients (n = 7) receiving ddI for 45 to 71 weeks also had a decrease (p = 0.018). It should be noted, however, that more research is required to evaluate the usefulness of this technique in assessing the disease status and monitoring the activity of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520538     DOI: 10.1089/aid.1992.8.1263

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  16 in total

1.  The scope of quantitative polymerase chain reaction assays in clinical molecular pathology.

Authors:  R D Malcomson; C T McCullough; D J Bruce; D J Harrison
Journal:  Clin Mol Pathol       Date:  1995-08

2.  Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.

Authors:  R S Tedder; S Kaye; C Loveday; I V Weller; D Jeffries; J Norman; J Weber; M Bourelly; R Foxall; A Babiker; J H Darbyshire
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

3.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

Review 5.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

Review 6.  Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

Authors:  S Hammer; C Crumpacker; R D'Aquila; B Jackson; J Lathey; D Livnat; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

7.  Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival.

Authors:  A Watson; J Ranchalis; B Travis; J McClure; W Sutton; P R Johnson; S L Hu; N L Haigwood
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals.

Authors:  H Zhang; O Bagasra; M Niikura; B J Poiesz; R J Pomerantz
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection.

Authors:  I Van Kerckhoven; K Fransen; M Peeters; H De Beenhouwer; P Piot; G van der Groen
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

10.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.